FDA warns Swedish sterile drugmaker Rechon Life Science over aseptic technique, weak investigations, cleaning and facility problems.
What happened
FDA inspected Rechon Life Science AB's drug manufacturing facility in Limhamn, Sweden, from August 26 to September 6, 2024. Investigators saw an operator touch a critical sterile surface of the ampoule filling line with a gloved hand, found the company's own procedure allowed this, and saw the same contact in a smoke study video. FDA also found weak investigations into rising microbe counts and into failed (out-of-specification) test results, an unvalidated decontamination process, sticky residue on cleanroom walls and floors, and peeling paint and rust in a room leading into an aseptic filling line.
What FDA found
Operators touched critical sterile parts of the filling line with gloved hands, and the company's written procedure said they could.
21 CFR 211.113(b)Investigations into repeated microbe finds in cleanrooms and on operators' gowning did not look at all possible sources and blamed talking and staff illness.
21 CFR 211.192Failed test results were thrown out as lab error without solid scientific proof and without checking whether manufacturing caused the failure.
21 CFR 211.192The decontamination process used on aseptic filling lines was not validated, and biological indicators used to test it came back positive.
21 CFR 211.42(c)(10)(v)Walls and floors in several cleanrooms were sticky and left visible residue when wiped, and fibers stuck to the walls.
21 CFR 211.42(c)(10)(v)A cleanroom that leads into an aseptic filling line had peeling paint on the ceiling and bubbled paint and rust at the bottom of the door.
21 CFR 211.58
What FDA wants
FDA tells the company to correct the violations promptly and to reply in writing with details of what it has done and how it will prevent recurrence. The reply should include independent risk assessments of contamination hazards, a review of invalidated out-of-specification results for U.S. products, and cleaning and facility remediation plans.
Who should pay attention
- companies that buy sterile injectable or ampoule products from this contract manufacturer
- marketers of U.S. drugs that list this site as a manufacturer
- quality teams running aseptic filling and cleanroom programs
This is a summary. Read the original letter on fda.gov.